Development of Novel Rifampicin-Derived P-Glycoprotein Activators/Inducers. Synthesis, In Silico Analysis and Application in the RBE4 Cell Model, Using Paraquat as Substrate

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Vilas Boas, Vânia ^a   Silva, Renata ^a   Palmeira, Andreia ^a   Sousa, Emília ^a   Ferreira, Luísa Maria ^b   Branco, Paula Sério ^b   Carvalho, Félix ^a   de Bastos, Maria Lourdes ^a   Remião, Fernando ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ELACRIDAR; MONO METHOXYLATED RIFAMPICIN; MULTIDRUG RESISTANCE PROTEIN; PARAQUAT; PERACETYLATED RIFAMPICIN; PROTEIN ANTIBODY; REDUCED RIFAMPICIN; RHODAMINE 123; RIFAMPICIN; RIFAMPICIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CELL STRAIN RBE4; CHEMICAL INTERACTION; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; FLOW CYTOMETRY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; WESTERN BLOTTING;

ACETYLATION; ANIMALS; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; CELL LINE, TRANSFORMED; COMPUTER SIMULATION; FLOW CYTOMETRY; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; P-GLYCOPROTEIN; PARAQUAT; RATS; RIFAMPIN; SPECTROPHOTOMETRY, INFRARED;

EID: 84883179970     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074425     Document Type: Article

References (55)

1. Kim RB, (2002) Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 34: 47-54. doi:10.1081/DMR-120001389. PubMed: 11996011.
2. Juliano RL, Ling V, (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162. doi:10.1016/0005-2736(76)90160-7. PubMed: 990323.
3. Adams DJ, Knick VC, (1995) P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine). Invest New Drugs 13: 13-21. doi:10.1007/BF02614215. PubMed: 7499103.
4. de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, et al. (2012) Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs 30: 443-449. doi:10.1007/s10637-010-9569-1. PubMed: 20963470.
5. Hirayama C, Watanabe H, Nakashima R, Nanbu T, Hamada A, et al. (2008) Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. Pharm Res 25: 827-835. doi:10.1007/s11095-007-9376-3. PubMed: 17934801.
6. Hung CC, Chiou MH, Teng YN, Hsieh YW, Huang CL, et al. (2013) Functional impact of ABCB1 variants on interactions between P-glycoprotein and methadone. PLOS ONE 8: e59419. doi:10.1371/journal.pone.0059419. PubMed: 23527191.
7. Meena AS, Sharma A, Kumari R, Mohammad N, Singh SV, et al. (2013) Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved. PLOS ONE 8: e61524. doi:10.1371/journal.pone.0061524. PubMed: 23613870.
8. Schinkel AH, Wagenaar E, Mol CA, van Deemter L, (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97: 2517-2524. doi:10.1172/JCI118699. PubMed: 8647944.
9. Ansbro MR, Shukla S, Ambudkar SV, Yuspa SH, Li L, (2013) Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference. PLOS ONE 8: e60334. doi:10.1371/journal.pone.0060334. PubMed: 23593196.
10. Hung CC, Liou HH, (2011) YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway. Invest New Drugs 29: 1337-1346. doi:10.1007/s10637-010-9496-1. PubMed: 20676745.
11. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, et al. (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17-24. PubMed: 1670642.
12. Slater LM, Sweet P, Stupecky M, Gupta S, (1986) Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 77: 1405-1408. doi:10.1172/JCI112450. PubMed: 3457021.
13. Fromm MF, (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25: 423-429. doi:10.1016/j.tips.2004.06.002. PubMed: 15276711.
14. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, et al. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84: 7735-7738. doi:10.1073/pnas.84.21.7735. PubMed: 2444983.
15. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, et al. (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287. doi:10.1177/38.9.1974900. PubMed: 1974900.
16. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, et al. (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 86: 695-698. doi:10.1073/pnas.86.2.695. PubMed: 2563168.
17. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502. doi:10.1016/0092-8674(94)90212-7. PubMed: 7910522.
18. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P, (1995) Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96: 1698-1705. doi:10.1172/JCI118214. PubMed: 7560060.
19. Dinis-Oliveira RJ, Remião F, Duarte JA, Ferreira R, Sánchez Navarro A, et al. (2006) P-glycoprotein induction: an antidotal pathway for paraquat-induced lung toxicity. Free Radic Biol Med 41: 1213-1224. doi:10.1016/j.freeradbiomed.2006.06.012. PubMed: 17015168.
20. Silva R, Carmo H, Dinis-Oliveira R, Cordeiro-da-Silva A, Lima SC, et al. (2011) In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells. Arch Toxicol 85: 315-326. doi:10.1007/s00204-010-0587-8. PubMed: 20857089.
21. Silva R, Carmo H, Vilas-Boas V, de Pinho PG, Dinis-Oliveira RJ, et al. (2013) Doxorubicin decreases paraquat accumulation and toxicity in Caco-2 cells. Toxicol Lett 217: 34-41. doi:10.1016/j.toxlet.2012.11.028. PubMed: 23220037.
22. Shapiro AB, Ling V, (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250: 130-137. doi:10.1111/j.1432-1033.1997.00130.x. PubMed: 9432000.
23. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, et al. (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104: 147-153. doi:10.1172/JCI6663. PubMed: 10411543.
24. Owen A, Goldring C, Morgan P, Park BK, Pirmohamed M, (2006) Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. Br J Clin Pharmacol 62: 237-242. doi:10.1111/j.1365-2125.2006.02587.x. PubMed: 16842400.
25. Bachmeier CJ, Beaulieu-Abdelahad D, Ganey NJ, Mullan MJ, Levin GM, (2011) Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharm Drug Dispos 32: 233-244. doi:10.1002/bdd.753. PubMed: 21446053.
26. Magnarin M, Morelli M, Rosati A, Bartoli F, Candussio L, et al. (2004) Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells. Eur J Pharmacol 483: 19-28. doi:10.1016/j.ejphar.2003.10.010. PubMed: 14709322.
27. Martin P, Riley R, Thompson P, Williams D, Back D, et al. (2010) Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells. Acta Pharmacol Sin 31: 51-65. doi:10.1038/aps.2009.187. PubMed: 20048746.
28. Saljé K, Lederer K, Oswald S, Dazert E, Warzok R, et al. (2012) Effects of rifampicin, dexamethasone, St. John's Wort and Thyroxine on maternal and foetal expression of Abcb1 and organ distribution of talinolol in pregnant rats. Basic Clin Pharmacol Toxicol 111: 99-105. PubMed: 22339773.
29. Pyta K, Przybylski P, Wicher B, Gdaniec M, Stefańska J, (2012) Intramolecular proton transfer impact on antibacterial properties of ansamycin antibiotic rifampicin and its new amino analogues. Org Biomol Chem 10: 2385-2388. doi:10.1039/c2ob00008c. PubMed: 22349158.
30. Roux F, Couraud PO, (2005) Rat brain endothelial cell lines for the study of blood-brain barrier permeability and transport functions. Cell Mol Neurobiol 25: 41-58. doi:10.1007/s10571-004-1376-9. PubMed: 15962508.
31. Moore JA, Reed DE, (1973) Diazomethane. Org Synth 5: 351-354.
32. Roux F, Durieu-Trautmann O, Chaverot N, Claire M, Mailly P, et al. (1994) Regulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells. J Cell Physiol 159: 101-113. doi:10.1002/jcp.1041590114. PubMed: 7908023.
33. Vilas-Boas V, Silva R, Guedes-de-Pinho P, Carvalho F, Bastos Mde L, et al. (2013) RBE4 cells are highly resistant to paraquat-induced cytotoxicity - studies on uptake and efflux mechanisms. J Appl Toxicol (In press).
34. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275. PubMed: 14907713.
35. Vilas-Boas V, Silva R, Gaio AR, Martins AM, Lima SC, et al. (2011) P-glycoprotein activity in human Caucasian male lymphocytes does not follow its increased expression during aging. Cytometry A 79: 912-919. PubMed: 21905209.
36. Palmeira A, Rodrigues F, Sousa E, Pinto M, Vasconcelos MH, et al. (2011) New uses for old drugs: pharmacophore-based screening for the discovery of P-glycoprotein inhibitors. Chem Biol Drugs Des 78: 57-72. doi:10.1111/j.1747-0285.2011.01089.x. PubMed: 21235729.
37. Palmeira A, Vasconcelos MH, Paiva A, Fernandes MX, Pinto M, et al. (2012) Dual inhibitors of P-glycoprotein and tumor cell growth: (re)discovering thioxanthones. Biochem Pharmacol 83: 57-68. doi:10.1016/j.bcp.2011.10.004. PubMed: 22044878.
38. Sterz K, Möllmann L, Jacobs A, Baumert D, Wiese M, (2009) Activators of P-glycoprotein: Structure-activity relationships and investigation of their mode of action. Chemmedchem 4: 1897-1911. doi:10.1002/cmdc.200900283. PubMed: 19777523.
39. Henmi K, Yoshida M, Yoshikawa N, Hirano T, (2008) P-glycoprotein functions in peripheral-blood CD4+ cells of patients with systemic lupus erythematosus. Biol Pharm Bull 31: 873-878. doi:10.1248/bpb.31.873. PubMed: 18451510.
40. Storch CH, Klimm HD, Heinrich T, Haefeli WE, Weiss J, (2007) Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells. Naunyn Schmiedebergs Arch Pharmacol 376: 135-143. doi:10.1007/s00210-007-0177-3. PubMed: 17653693.
41. Daoud R, Kast C, Gros P, Georges E, (2000) Rhodamine 123 binds to multiple sites in the multidrug resistance protein (MRP1). Biochemistry 39: 15344-15352. doi:10.1021/bi0020574. PubMed: 11112520.
42. Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, et al. (2005) Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 11: 2320-2326. doi:10.1158/1078-0432.CCR-04-1725. PubMed: 15788683.
43. Regina A, Koman A, Piciotti M, El Hafny B, Center MS, et al. (1998) Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 71: 705-715. PubMed: 9681461.
44. Yang L, Fawcett JP, Østergaard J, Zhang H, Tucker IG, (2012) Mechanistic studies of the effect of bile salts on rhodamine 123 uptake into RBE4 cells. Mol Pharm 9: 29-36. doi:10.1021/mp200201y. PubMed: 22050323.
45. Lorian V, Finland M, (1969) In vitro effect of rifampin on mycobacteria. Appl Microbiol 17: 202-207. PubMed: 4975656.
46. Rees RJ, Pearson JM, Waters MF, (1970) Experimental and clinical studies on rifampicin in treatment of leprosy. BMJ 1: 89-92. doi:10.1136/bmj.1.5688.89. PubMed: 4903972.
47. McIlleron H, Meintjes G, Burman WJ, Maartens G, (2007) Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 196 (Suppl 1):: S63-S75. doi:10.1086/518655. PubMed: 17624828.
48. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD, (1996) P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A 93: 4001-4005. doi:10.1073/pnas.93.9.4001. PubMed: 8633005.
49. Shapiro AB, Ling V, (1997) Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 53: 587-596. doi:10.1016/S0006-2952(96)00826-X. PubMed: 9105411.
50. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, et al. (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58: 624-632. PubMed: 10953057.
51. Safa AR, (1993) Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells. Cancer Invest 11: 46-56. doi:10.3109/07357909309020260. PubMed: 8093677.
52. Safa AR, (1998) Photoaffinity labels for characterizing drug interaction sites of P-glycoprotein. Methods Enzymol 292: 289-307. doi:10.1016/S0076-6879(98)92023-7. PubMed: 9711562.
53. Safa AR, (2004) Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr Med Chem Anti Cancer Agents 4: 1-17. doi:10.2174/1568011043482142. PubMed: 14754408.
54. Loo TW, Bartlett MC, Clarke DM, (2009) Identification of residues in the drug translocation pathway of the human multidrug resistance P-glycoprotein by arginine mutagenesis. J Biol Chem 284: 24074-24087. doi:10.1074/jbc.M109.023267. PubMed: 19581304.
55. Vilas-Boas V, Silva R, Nunes C, Reis S, Ferreira L, et al. (2013) Mechanisms of P-gp inhibition and effects on membrane fluidity of a new rifampicin derivative, 1,8-dibenzoyl-rifampicin. Toxicol Lett.